The White House reportedly pulled Heidi Overton, the administration’s nominee to lead the FDA, amid uncertainty around Senate support. The abrupt change reopens questions about the regulator’s near-term leadership stability and agenda-setting. For biotech and pharma, FDA commissioner leadership affects everything from inspection and enforcement priorities to the pace and framing of review policies across drugs, biologics, and devices. Even without policy announcements in this item, the personnel uncertainty creates planning risk for companies with submissions timed to leadership expectations. Market participants typically treat leadership disruptions as a potential catalyst for process changes, particularly around complex review programs and high-profile regulatory pathways. Companies may respond by tightening contingency plans for timelines and follow-up questions. The headline driver here is process-related risk rather than new regulatory science, but it has immediate operational relevance for stakeholders reliant on FDA execution.